[Antiatherogenic effects of angiotensin converting enzyme inhibitors from positions (point of view) of evidence based medicine. Part I].
In a series of two articles the authors present data from controlled trials in which cardio-, cerebro-, and vasoprotective effects of angiotensin converting enzyme inhibitors (ACEI) were assessed. The first communication deals with results of randomized studies in most of which no objective proof of antiischemic (antianginal) effects of ACEI was obtained. In seven placebo controlled studies effects of ACEI were evaluated by means of quantitative angiography (or intravascular ultrasound) and in none of them favorable effect of long-term therapy with ACEI on progression of coronary atherosclerosis and restenosis rate after balloon coronary angioplasty was revealed. Retardation of progression of carotid artery atherosclerosis under influence of ACEI was noted in 2 of 4 trials. But diagnostic value of noninvasive methods which were used in these trials is considerably lower than that of angiography or intravascular ultrasound.